The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Matthew Park - Cantor Fitzgerald - Analyst
: This is Matthew Park on for Ross. I was just hoping if you could provide more color in terms of the scale of the pilot launch and I guess your time
line to full launch and when we should start to see revenue coming forward.
Question: Matthew Park - Cantor Fitzgerald - Analyst
: Got it. That's helpful. And then I guess following up on that, would you walk us through your pipeline of additional contracts and any conversations
you are having right now with large centers?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 13, 2024 / 12:30PM, PAVM.OQ - Q2 2024 PAVmed Inc Earnings Call
Question: Matthew Park - Cantor Fitzgerald - Analyst
: Got it. That's helpful. And then I guess just one more on my end. coming from -- under pending additional financing, have you guys provided
longer-term guidance on when you expect to submit the monitor for approval? And I guess, the steps that you guys take to get there?
Question: Anthony Vendetti - Maxim Group - Analyst
: Dennis, I think you may have answered the question, but I just want to clarify. So when you're talking about the financing, you were talking about
for Veris, not for the incubator, correct?
Question: Anthony Vendetti - Maxim Group - Analyst
: Okay. Great. And at this point, though, it's not a spinoff into an IPO like Lucid, correct?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 13, 2024 / 12:30PM, PAVM.OQ - Q2 2024 PAVmed Inc Earnings Call
Question: Anthony Vendetti - Maxim Group - Analyst
: Agreed. Yes. No, that makes sense. So based on your best estimate, you expect Veris, you expect to have funding for Veris in place before the end
of the year and then submit to the FDA by mid-'25. Is that correct?
Question: Ed Woo - Ascendiant Capital Markets LLC - Analyst
: I had a very general question about valuations. Have you seen valuations change significantly in terms of when you're going out trying to raise
funding for the incubator as well as for Veris?
| 
